07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

Pipex, University of California deal

Pipex received an exclusive, worldwide license from the university to develop and commercialize oral dnaJP1 (formerly AT-001) for autoimmune diseases. Pipex said Androclus Therapeutics (San Diego, Calif.), which had been developing the compound, returned rights...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Clinical News

DnaJP1: Phase II data

In a double-blind, placebo-controlled, U.S. Phase II trial in 160 patients, AT-001 missed the primary endpoint of AUC of ACR20 response rates at days 112, 140 and 168 (p=0.099). A post hoc analysis showed that...
08:00 , Nov 7, 2005 |  BioCentury  |  Product Development

Reviving oral tolerance

Autoimmune startup Androclus Therapeutics aims to rekindle interest in oral tolerance therapies with its AT-001 dnaJP1 peptide against proinflammatory proteins in rheumatoid arthritis. Although AT-001 missed its target using an unconventional primary endpoint in a...
02:58 , Nov 3, 2005 |  BC Extra  |  Clinical News

Androclus' AT-001 fails RA Phase II

Androclus (San Diego, Calif.) said oral AT-001 missed the primary endpoint of under the curve of ACR20 response rates at days 112, 140 and 168 in a double-blind, placebo-controlled, U.S. Phase II trial to treat...